Search This Blog

Tuesday, January 7, 2020

VTv Therapeutics after market as Perelman boosts stake

VTv Therapeutics (NASDAQ:VTVT) is up 7% after hours following a boost to the majority stake held by Ron Perelman’s MacAndrews & Forbes.
Today the company exercised a right to cause MacAndrews & Forbes to buy 1.25M shares at $1.60 each – part of an agreement between the two reached Dec. 23.
MacAndrews & Forbes funded $2M to the company in return.
Posted by at No comments:

Cumberland Pharma rolls out new ibuprofen product

Cumberland Pharmaceuticals (NASDAQ:CPIX) has announced the launch of a new ready-to-use Caldolor product, following previous FDA approval for a new delivery method.
The ibuprofen product now comes in a ready-to-use bag that can be administered without dilution, the company says. the bag contains 800 mg of ibuprofen in a 200 mL patented low-sodium formulation for injection.
“We have been encouraged by the significant number of physicians who have incorporated Caldolor into their pain management regimens as a way to combat the negative effects of opioid use,” says CEO A.J. Kazimi.
Shares are up 3% after hours.
Posted by at No comments:

Cellect Bio up on new patents

Thinly traded micro cap Cellect Biotechnology (NASDAQ:APOP) rockets 165% premarket on robust volume in reaction to its announcement that it has been notified that its patent applications in Europe and Israel for a cell-based product and a method of manufacturing a stem and progenitor cell population with enhanced activity by short incubation with an apoptotic ligand will be granted.
The applications cover an ex vivo method for obtaining an improved population of stem and progenitor cells with enhanced engraftment characteristics by activation of TNF family receptors.
The Company’s previous patents covered the negative selection exerted by the ApoGraft process and product translated into clinical safety superiority. The latest patent applications describe and protect the positive effect that the same molecules have on stem cells and translates to the efficacy of the transplanted cells and the yields of the manufacturing processes for clinical use.
Posted by at No comments:

Hepion Pharma up 15% premarket potential of CRV431 in NASH

Nano cap Hepion Pharmaceuticals (NASDAQ:HEPA) is up 15% premarket on modest volume on the heels of a just-published paper supporting the rationale of cyclophilin inhibition for the potential treatment of nonalcoholic steatohepatitis (NASH).
The comprehensive review of studies investigating cyclophilins in NASH and NASH-related liver disease, authored by certain Hepion executives, is in the latest edition of the journal Expert Opinion on Investigational Drugs. 
The authors assert that the scientific literature provides “abundant evidence” that cyclophilin inhibition, the mechanism of action of candidate CRV431, could help resolve a range of pathophysiological processes in NASH, including inflammation, mitochondrial dysfunction, liver cell death and fibrotic scarring.
Posted by at No comments:

Apellis Pharma’s APL-2 successful in PNH study; shares up

Apellis Pharmaceuticals (NASDAQ:APLS) jumps 49% premarket on robust volume in reaction to positive results from a Phase 3 clinical trial, PEGASUS, evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria (PNH).
The study met the primary endpoint demonstrating superiority over Alexion Pharmaceuticals’ (NASDAQ:ALXN) Soliris (eculizumab) as measured by the change from baseline in hemoglobin level at week 16. Specifically, patients receiving pegcetacoplan showed an adjusted mean hemoglobin increase of 3.8 g/dL compared to a mean decrease of -1.5 g/dL in the eculizumab arm (p<0.0001).
Pegcetacoplan showed non-inferiority to eculizumab on transfusion avoidance and absolute reticulocyte count.
All patients who completed the randomization period in both groups (n=77/80) entered the 32-week open-label pegcetacoplan treatment period.
Detailed results will be submitted for presentation at a future medical conference.
Posted by at No comments:

Curis up 9% premarket on deal with ImmuNext in cancer

Thinly traded nano cap Curis (NASDAQ:CRIS) is up 9% premarket on light volume in reaction to its agreement with ImmunNext for potential exclusive global rights to develop and commercialize its anti-VISTA antibodies, including lead drug CI-8993 (formerly Johnson & Johnson’s JNJ-61610588), for the treatment of cancer (J&J returned the rights to ImmuNext after a Phase 1 study).
Under the terms of the deal, Curis will pay ImmuNext an undisclosed amount upfront in exchange for an option to exclusively license the latter’s candidate portfolio in oncology. The option is exercisable upon the earlier of four years from the signing of the agreement or 90 days after the database lock in the first Phase 1a/1b study that meets the clinical endpoints. If Curis opts in, it will pay ImmuNext an option exercise fee, milestones and royalties on net sales.
VISTA is a novel negative checkpoint ligand akin to PD-1/PD-L1 that suppresses T cell activation.
Posted by at No comments:

Can-Fite up ahead namodenoson data presentation

Nano cap Can-Fite BioPharma (NYSEMKT:CANF) is up 11% premarket on increased volume on the heels of its announcement that the principal investigator of a Phase 2 clinical trial evaluating namodenoson (CF102) for the second-line treatment of liver cancer with cirrhosis will present safety and efficacy data tomorrow, January 8, at the Israeli Society of Clinical Oncology and Radiotherapy annual conference.
Although the study failed to achieve the primary endpoint of overall survival, there was a positive effect in a subpopulation of patients with Child Pugh B7 (moderately severe liver disease).
Posted by at No comments:
Subscribe to: Posts (Atom)